Vetoquinol SA (0O1O.L)
EUR 76.5
(0.0%)
EUR 76.5
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -129.83 Million EUR | -70.19% |
| 2022 | -76.28 Million EUR | -42.28% |
| 2021 | -53.61 Million EUR | -1069.38% |
| 2020 | -4.58 Million EUR | 93.67% |
| 2019 | -72.42 Million EUR | 34.73% |
| 2018 | -110.95 Million EUR | -13.69% |
| 2017 | -97.59 Million EUR | -23.5% |
| 2016 | -79.02 Million EUR | -47.08% |
| 2015 | -53.72 Million EUR | -60.01% |
| 2014 | -33.57 Million EUR | 28.28% |
| 2013 | -46.82 Million EUR | -50.04% |
| 2012 | -31.2 Million EUR | -19.12% |
| 2011 | -26.19 Million EUR | -18.83% |
| 2010 | -22.04 Million EUR | -186.22% |
| 2009 | 25.56 Million EUR | 232.4% |
| 2008 | -19.31 Million EUR | 52.12% |
| 2007 | -40.33 Million EUR | -294.19% |
| 2006 | 20.77 Million EUR | -13.45% |
| 2005 | 23.99 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -156.53 Million EUR | 0.0% |
| 2023 Q4 | -129.83 Million EUR | 0.0% |
| 2023 FY | -129.83 Million EUR | -70.19% |
| 2023 Q2 | -83.98 Million EUR | 0.0% |
| 2022 Q4 | -76.28 Million EUR | 0.0% |
| 2022 Q2 | -23.73 Million EUR | 0.0% |
| 2022 FY | -76.28 Million EUR | -42.28% |
| 2021 Q2 | -16.21 Million EUR | 0.0% |
| 2021 Q4 | -53.61 Million EUR | 0.0% |
| 2021 FY | -53.61 Million EUR | -1069.38% |
| 2020 Q2 | -91.25 Million EUR | 0.0% |
| 2020 Q4 | -4.58 Million EUR | 0.0% |
| 2020 FY | -4.58 Million EUR | 93.67% |
| 2019 FY | -72.42 Million EUR | 34.73% |
| 2019 Q2 | -36.39 Million EUR | 0.0% |
| 2019 Q4 | -72.42 Million EUR | 0.0% |
| 2018 FY | -110.95 Million EUR | -13.69% |
| 2018 Q4 | -110.95 Million EUR | 0.0% |
| 2018 Q2 | -92.86 Million EUR | 0.0% |
| 2017 FY | -97.59 Million EUR | -23.5% |
| 2017 Q4 | -97.59 Million EUR | 0.0% |
| 2017 Q2 | -76.2 Million EUR | 0.0% |
| 2016 Q2 | -54.4 Million EUR | 0.0% |
| 2016 FY | -79.02 Million EUR | -47.08% |
| 2016 Q4 | -78.62 Million EUR | 0.0% |
| 2015 FY | -53.72 Million EUR | -60.01% |
| 2015 Q2 | -25.62 Million EUR | 0.0% |
| 2015 Q4 | -53.72 Million EUR | 0.0% |
| 2014 Q2 | -5.99 Million EUR | 0.0% |
| 2014 FY | -33.57 Million EUR | 28.28% |
| 2014 Q4 | -33.57 Million EUR | 0.0% |
| 2013 Q4 | -46.82 Million EUR | 0.0% |
| 2013 FY | -46.82 Million EUR | -50.04% |
| 2013 Q2 | -26.06 Million EUR | 0.0% |
| 2012 Q4 | -31.2 Million EUR | 0.0% |
| 2012 Q2 | -73.83 Million EUR | 0.0% |
| 2012 FY | -31.2 Million EUR | -19.12% |
| 2011 Q4 | -26.19 Million EUR | 0.0% |
| 2011 FY | -26.19 Million EUR | -18.83% |
| 2010 Q2 | -9.09 Million EUR | 0.0% |
| 2010 Q4 | -22.04 Million EUR | 0.0% |
| 2010 FY | -22.04 Million EUR | -186.22% |
| 2009 Q4 | 25.56 Million EUR | 0.0% |
| 2009 FY | 25.56 Million EUR | 232.4% |
| 2008 FY | -19.31 Million EUR | 52.12% |
| 2007 FY | -40.33 Million EUR | -294.19% |
| 2006 FY | 20.77 Million EUR | -13.45% |
| 2005 FY | 23.99 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | -115.167% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 709.187% |
| Valneva SE | 82.73 Million EUR | 256.928% |
| AB Science S.A. | 13.03 Million EUR | 1096.057% |
| Nanobiotix S.A. | -29.8 Million EUR | -335.691% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | -47113.091% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | -600.907% |
| BioSenic S.A. | 28.04 Million EUR | 562.972% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 33.918% |
| Formycon AG | 2.45 Million EUR | 5397.266% |